In a recent meta-analysis using data from 27 clinical studies with over 7000 patients with diabetes or chronic kidney disease, SGLT2 inhibitors were found to reduce the risk of the composite CV outcome, hospitalized or fatal heart failure, and myocardial infarction. Here, SLC5A2 is linked to heart failure.